Satsuki Owatari

Kagoshima, 8920853, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications

Correction: Chimeric SF-25 monoclonal antibody as a targeted therapy for SLC3A2 in adult T-cell leukemia/lymphoma.

Correction: Chimeric SF-25 monoclonal antibody as a targeted therapy for SLC3A2 in adult T-cell leukemia/lymphoma.

Journal: Scientific reports
Published: October 01, 2025

A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for older patients with adult T-cell leukemia/lymphoma.

A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for older patients with adult T-cell leukemia/lymphoma.

Journal: Blood
Published: December 24, 2024

Chimeric SF-25 monoclonal antibody as a targeted therapy for SLC3A2 in adult T-cell leukemia/lymphoma.

Chimeric SF-25 monoclonal antibody as a targeted therapy for SLC3A2 in adult T-cell leukemia/lymphoma.

Journal: Scientific reports
Published: November 15, 2024

A decrease in newly diagnosed patients with adult T-cell leukemia/lymphoma in Kagoshima, a highly endemic area of HTLV-1 in southwestern Japan.

A decrease in newly diagnosed patients with adult T-cell leukemia/lymphoma in Kagoshima, a highly endemic area of HTLV-1 in southwestern Japan.

Journal: Leukemia & lymphoma
Published: February 11, 2023

Identification of putative noncanonical driver mutations in patients with essential thrombocythemia.

Identification of putative noncanonical driver mutations in patients with essential thrombocythemia.

Journal: European journal of haematology
Published: October 28, 2022

VCAP-AMP-VECP as a preferable induction chemotherapy in transplant-eligible patients with aggressive adult T-cell leukemia-lymphoma: a propensity score analysis.

VCAP-AMP-VECP as a preferable induction chemotherapy in transplant-eligible patients with aggressive adult T-cell leukemia-lymphoma: a propensity score analysis.

Journal: Bone marrow transplantation
Published: October 14, 2018

Outcomes of patients with relapsed aggressive adult T-cell leukemia-lymphoma: clinical effectiveness of anti-CCR4 antibody and allogeneic hematopoietic stem cell transplantation.

Outcomes of patients with relapsed aggressive adult T-cell leukemia-lymphoma: clinical effectiveness of anti-CCR4 antibody and allogeneic hematopoietic stem cell transplantation.

Journal: Haematologica
Published: January 27, 2018

Clinical significance of cutaneous adverse reaction to mogamulizumab in relapsed or refractory adult T-cell leukaemia-lymphoma.

Clinical significance of cutaneous adverse reaction to mogamulizumab in relapsed or refractory adult T-cell leukaemia-lymphoma.

Journal: British journal of haematology
Published: April 04, 2017

Development of a modified prognostic index for patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger: possible risk-adapted management strategies including allogeneic transplantation.

Development of a modified prognostic index for patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger: possible risk-adapted management strategies including allogeneic transplantation.

Journal: Haematologica
Published: January 23, 2017

Acute Myeloid Leukemia Diagnosed 5 Years after Adult T-Cell Leukemia/Lymphoma.

Acute Myeloid Leukemia Diagnosed 5 Years after Adult T-Cell Leukemia/Lymphoma.

Journal: Journal of clinical and experimental hematopathology : JCEH
Published: June 25, 2015
Showing 1-10 of 10

Last Updated: 09/26/2026